Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant chemotherapy vs chemoradiotherapy in locally advanced resectable rectal cancer (FRENCH-GRECCAR-PRODIGE)
2018-002717-35Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of oxaliplatin, irinotecan, fluorouracil and capecitabine in rectal cancer (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: 3-year progression-free survival. Started Oct 2018; status: active.
02
Drugs
oxaliplatinirinotecanfluorouracilcapecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on 2018-002717-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002717-35.